Systemic mastocytosis with associated hematologic neoplasm (SM-AHN) presents unique diagnostic and treatment challenges. In this Medscape-certified activity, experts discuss the complex patient journey, from delayed diagnosis to individualized…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
A recent study shows that malignant high-grade PINs have a greater expression of PTOV1 (prostate tumor overexpressed-1) compared with benign lesions, and as expression of PTOV1 decreased, so…
Dan Labriola, ND, Director, Naturopathic Services, Swedish Cancer Institute, Seattle, WA, discusses complementary therapy with the treatment of cancer. References and Resources Eliott JA, Kealey CP, Olver IN.…
Saul E. Rivkin, MD, Founder of the Marsha Rivkin Center for Ovarian Cancer, Medical Oncologist, Swedish Cancer Institute, Seattle, WA, discusses the future of testing for early stage…
Elise N. Everett, MS, MD, Gynecologic Oncologist, Swedish Cancer Institute, Seattle WA, discusses robotic surgery. References and Resources Sert B, Abeler V. Robotic radical hysterectomy in early-stage cervical…
Saul E. Rivkin, MD, Founder of the Marsha Rivkin Center for Ovarian Cancer, Medical Oncologist, Swedish Cancer Institute, Seattle, WA, discusses ovarian cancer and stresses the importance of…
Jed Gorden, MD, Director, Interventional Pulmonology, Swedish Cancer Institute, Seattle, WA, discusses interventional pulmonology and novel techniques for the diagnosis of lung diseases. References and Resources Gasparini S.…
Ralph W. Aye, MD, Program Leader, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA, discusses the possibility of the use of sputum analysis for lung cancer screening. References…
Ralph W. Aye, MD, Program Leader, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA, shares his thoughts on the cost of lung cancer screening. Sponsored by The Doctor’s…
For patients on continuous medication for pain relief in late-stage illness, the FDA has approved methylnaltrexone bromide (Relistor) injection for treatment of opioid-induced constipation. References and Resources FDA…
According to results of a multicenter randomized clinical trial, patients with advanced NSCLC derived no benefit from the addition of sorafenib (Nexavar) to chemotherapy. References and Resources Scagliotti…
